-
Sep 20, 2023
BRISBANE, Calif. --(BUSINESS WIRE)--Sep. 20, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that it will participate in the Jefferies Cell & Genetic Medicine Summit, to be held from September 26-27, 2023 in New York City .
-
Aug 08, 2023
Conference call and webcast scheduled for Tuesday, August 8 , 4:30 p.m. Eastern Time . BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 8, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2023 financial results.
-
Aug 01, 2023
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 1, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2023 financial results after the market closes on Tuesday, August 8, 2023 .
-
Jul 20, 2023
BRISBANE, Calif. & BOSTON --(BUSINESS WIRE)--Jul. 20, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a clinical-stage genomic medicine company and Chroma Medicine, Inc. (Chroma), a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced they have entered
-
Jul 17, 2023
BRISBANE, Calif. --(BUSINESS WIRE)--Jul. 17, 2023-- Sangamo Therapeutics, Inc. (“Sangamo”, Nasdaq: SGMO), a genomic medicine company, today announced it has signed an evaluation and option agreement with Prevail Therapeutics (“Prevail”), a wholly owned subsidiary of Eli Lilly and Company, through
-
Jun 29, 2023
BRISBANE, Calif. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 29, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR), today announced the parties have entered into a definitive license agreement for a potential treatment of
-
May 22, 2023
BRISBANE, Calif. --(BUSINESS WIRE)--May 22, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product
-
May 16, 2023
BRISBANE, Calif. --(BUSINESS WIRE)--May 16, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer , M.D., as Chief Medical Officer. She will serve on the Executive Leadership team and report to Nathalie Dubois-Stringfellow ,
-
May 02, 2023
BRISBANE, Calif. --(BUSINESS WIRE)--May 2, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for presentation at the 26 th ASGCT Annual Meeting being held May
-
Apr 26, 2023
Strong clinical momentum continues in Phase 1/2 STAAR study in Fabry disease with 20 patients dosed in total. Dosed third patient in cohort 1 of Phase 1/2 CAR-Treg STEADFAST study for TX200 in HLA A2 mismatched kidney transplantation. Unveiled Nav1.7 target to treat chronic neuropathic pain as